MDM4 and cancer: The enhanced activity observed from the peptide-based dual inhibitors in cancers, which carry high levels of MDMX, supports the development of small-molecule selective or dual MDMX/2 inhibitors, and efforts toward this end will be summarized here—specifically for compounds with confirmed binding to MDMX with co-crystal structures.